You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Biomarkers: to be or not to be
  1. Sule Yavuz,
  2. Lars Rönnblom
  1. Department of Medical Sciences, Rheumatology and Science for Life Laboratories, Uppsala University, Uppsala, Sweden
  1. Correspondence to Professor Sule Yavuz, Department of Medical Sciences, Rheumatology and Science for Life Laboratories, Uppsala University, Uppsala 75185, Sweden; sule.yavuz{at}medsci.uu.se

https://doi.org/10.1136/annrheumdis-2018-214608

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article by van den Hoogen et al 1 describing galectin-9 (Gal-9) as a novel, easy-to-measure biomarker for the interferon (IFN) signature in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). We support the views expressed by the authors that IFN signature is an important biomarker in disease activity in SLE and there is certainly a need for easier to measure biomarkers for IFN signature, but to suggest that Gal-9 could aid in clinical decision making in steering anti-IFN therapy seems premature. We know that the common …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors Both authors contributed equally to writing and editing this letter.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles